Literature DB >> 6751983

B-lymphocyte mitogenicity in vitro of a synthetic lipopeptide fragment derived from bacterial lipoprotein.

W G Bessler, R B Johnson, K Wiesmüller, G Jung.   

Abstract

Lipoprotein from the outer membrane of Escherichia coli is a potent mitogen towards lymphocytes of different species. A lipopeptide fragment corresponding to the N-terminal part of the lipoprotein was prepared by chemical synthesis. The mitogenicity of the compound was demonstrated by measuring the incorporation of both [3H]thymidine into DNA and [3H]uridine into RNA at various times after the addition of lipopeptide to mouse spleen cell cultures. The lipopeptide also activated B-lymphocyte development into immunoglobulin secreting cells, as shown by a hemolytic plaque assay. The mitogenicity of the synthetic compound was comparable to the activity of the B-lymphocyte mitogens lipoprotein and lipopolysaccharide. Thus, it was shown that a fragment of a bacterial surface component prepared by chemical synthesis, exhibits a marked biological activity.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6751983

Source DB:  PubMed          Journal:  Hoppe Seylers Z Physiol Chem        ISSN: 0018-4888


  10 in total

1.  Synergistic effect of Nod1 and Nod2 agonists with toll-like receptor agonists on human dendritic cells to generate interleukin-12 and T helper type 1 cells.

Authors:  Hiroyuki Tada; Setsuya Aiba; Ken-Ichiro Shibata; Toshiaki Ohteki; Haruhiko Takada
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

Review 2.  Immunomodulating peptides.

Authors:  G H Werner; F Floc'h; D Migliore-Samour; P Jollès
Journal:  Experientia       Date:  1986-05-15

3.  Temperature- and time-dependent changes in TLR2-activated microglial NF-κB activity and concentrations of inflammatory and anti-inflammatory factors.

Authors:  Tomohiro Matsui; Moe Tasaki; Takahiro Yoshioka; Yukari Motoki; Hidehiro Tsuneoka; Junzo Nojima
Journal:  Intensive Care Med       Date:  2012-06-01       Impact factor: 17.440

4.  Relationship between structures and biological activities of mycoplasmal diacylated lipopeptides and their recognition by toll-like receptors 2 and 6.

Authors:  Tsugumi Okusawa; Mari Fujita; Jun-Ichiro Nakamura; Takeshi Into; Motoaki Yasuda; Atsutoshi Yoshimura; Yoshitaka Hara; Akira Hasebe; Douglas T Golenbock; Manabu Morita; Yoshio Kuroki; Tomohiko Ogawa; Ken-Ichiro Shibata
Journal:  Infect Immun       Date:  2004-03       Impact factor: 3.441

5.  Antagonistic antibody prevents toll-like receptor 2-driven lethal shock-like syndromes.

Authors:  Guangxun Meng; Mark Rutz; Matthias Schiemann; Jochen Metzger; Alina Grabiec; Ralf Schwandner; Peter B Luppa; Frank Ebel; Dirk H Busch; Stefan Bauer; Hermann Wagner; Carsten J Kirschning
Journal:  J Clin Invest       Date:  2004-05       Impact factor: 14.808

6.  A defined fragment of bacterial protein I (OmpF) is a polyclonal B-cell activator.

Authors:  M Vordermeier; K Stäb; W G Bessler
Journal:  Infect Immun       Date:  1986-01       Impact factor: 3.441

7.  Polyclonal activation of B-lymphocytes in vivo by Salmonella typhimurium lipoprotein.

Authors:  R B Johnson; S Köhl; W G Bessler
Journal:  Infect Immun       Date:  1983-03       Impact factor: 3.441

8.  The impact of single and pairwise Toll-like receptor activation on neuroinflammation and neurodegeneration.

Authors:  Karen Rosenberger; Katja Derkow; Paul Dembny; Christina Krüger; Eckart Schott; Seija Lehnardt
Journal:  J Neuroinflammation       Date:  2014-09-20       Impact factor: 8.322

9.  Toll-like receptor 2 agonist exacerbates renal injury in diabetic mice.

Authors:  Fanglin Li; Ningyu Zhang; Zhiming Li; Lihua Deng; Jianjie Zhang; Yunfeng Zhou
Journal:  Exp Ther Med       Date:  2017-01-05       Impact factor: 2.447

Review 10.  Targeting TLR2 for vaccine development.

Authors:  Afonso P Basto; Alexandre Leitão
Journal:  J Immunol Res       Date:  2014-06-26       Impact factor: 4.818

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.